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ABSTRACT
Introduction: Pulmonary arterial hypertension
(PAH) is associated with poor prognosis despite
significant recent advances in its treatment. An
intravenous formulation of epoprostenol
sodium containing glycine and mannitol
(epoprostenol GM; GlaxoSmithKline, London,
UK) is widely used to treat PAH. A new
formulation of epoprostenol sodium
containing arginine and sucrose excipients
(epoprostenol AS; Actelion Pharmaceuticals
Japan Ltd., Tokyo, Japan) shows better stability
at room temperature after preparing diluted
solutions. The primary objective of this study
was to evaluate the safety and tolerability of
switching from epoprostenol GM to
epoprostenol AS in Japanese patients with
PAH. The authors also evaluated the efficacy
and treatment satisfaction after switching
formulations.
Methods: This was a two-site, open-label,
single-arm, Phase 3b study. Eight adult
Japanese PAH patients (seven females) treated
with a stable dose of epoprostenol GM
for C30 days were switched to epoprostenol AS
and followed for 12 weeks. Outcomes included
safety, changes from baseline to 12 weeks in
pulmonary hemodynamic factors (pulmonary
vascular resistance, mean pulmonary arterial
pressure, and cardiac output), and treatment
satisfaction, assessed using the Treatment
Satisfaction Questionnaire for Medication
(TSQM-9).
Results: The mean (range) age and time since
diagnosis of PAH were 48 (25–69) years and 6.2
(0.6–13.9) years, respectively. There were no
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unexpected safety or tolerability concerns after
switching formulations. The epoprostenol dose
was maintained after switching formulations.
There were no significant changes in pulmonary
hemodynamic factors from baseline to week 12.
Regarding treatment satisfaction, there was a
significant improvement in convenience, which
is demonstrated in the score of the domain
increased from 51.40 ± 10.19 at baseline to
58.33 ± 12.96 at week 12 (P\0.05).
Conclusions: Switching from epoprostenol GM
to the same dose of epoprostenol AS was well
tolerated over 12 weeks of treatment, and
pulmonary hemodynamics were maintained.
Switching to epoprostenol AS was also associated
with improvements in treatment satisfaction
(convenience). Clinical Trials: JapicCTI-122017.
Keywords: Efficacy; Epoprostenol;
Epoprostenol formulations; Japanese patients;
Prostacyclin; Pulmonary arterial hypertension;
Pulmonary hemodynamic factors; Safety;
Treatment satisfaction
INTRODUCTION
Pulmonary arterial hypertension (PAH) is a
progressive disease with poor prognosis. It is
generally characterized by constriction of
pulmonary arteries and vascular remodeling.
Right ventricular afterload (right ventricular
hypertrophy and enlargement) is increased
because of elevated pulmonary arterial
pressure and pulmonary vascular resistance,
which ultimately leads to right cardiac failure
and death [1]. Subjective symptoms of PAH
include exertional dyspnea, fatigability,
palpitations, chest pain, and syncope [2].
Although the underlying mechanisms of
PAH are not fully understood, vascular
endothelial abnormalities cause an imbalance
between vasoconstricting and vasodilating
factors. In this situation, vasoconstricting
factors exert a greater influence and increase
shear stress. It is generally thought that
remodeling of the pulmonary arterial media
and narrowing of the pulmonary intravascular
lumens due to increased cell proliferation are
responsible for this imbalance [3–5].
Prostacyclin (PGI2) agents with various
modes of action, endothelin receptor
antagonists, and phosphodiesterase-5
inhibitors are available for the treatment of
PAH. Oral administration of any of these drugs
is recommended for patients with PAH of World
Health Organization (WHO) functional Class III
or lower. For patients with Class IV PAH,
continuous intravenous administration of PGI2
is recommended. Concomitant treatment with
several drugs having different modes of action is
recommended if the clinical response to
monotherapy is inadequate [6–8].
PGI2 is a metabolite of arachidonic acid and
plays an important role in maintaining
pulmonary vascular homeostasis. It is
produced by endocapillary cells, and acts as a
potent vasodilator and inhibits platelet
aggregation. Accordingly, the PGI2 system
plays an important role in the inhibition of
vascular smooth muscle cell proliferation and
helps to protect the vascular endothelium. A
small decline in the function of the PGI2 system
leads to an imbalance between vasoconstrictors
and vasodilators, and appears to contribute to
the development of PAH [9–11].
Based on these findings, compounds that
target prostacyclin receptors have been
developed and are used clinically to treat PAH.
One such example is intravenous epoprostenol
sodium, a synthetic PGI2 analog, which is
prepared as a formulation containing glycine
and mannitol as excipients (epoprostenol GM,
GlaxoSmithKline, London, UK). Continuous
460 Adv Ther (2013) 30:459–471
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intravenous therapy with epoprostenol GM was
reported to improve pulmonary hemodynamic
factors, exercise tolerance, and the prognosis of
PAH [12]. However, one limitation of this
formulation is that the prepared solution is
thermally unstable, and needs to be
administered within 8 h at room temperature
(1–30 C) or within 24 h if cooled to 2–8 C
using frozen gel packs. Consequently, the
medication cassette containing the solution
has to be maintained at 2–8 C using a frozen
gel pack for the entire 24-h infusion period [13].
To overcome this limitation, another
formulation of epoprostenol sodium, containing
arginine and sucrose as excipients (Actelion
Pharmaceuticals Japan Ltd., Tokyo, Japan;
hereafter, epoprostenol AS), was developed to
improve the convenience of using epoprostenol
to treat PAH as the new formulation is stable for
24 h at room temperature [14].
To date, however, few studies have examined
the safety, potential effects on hemodynamic
factors, or treatment satisfaction associated with
switching formulationsof epoprostenol inpatients
with PAH [15]. Therefore, the authors performed a
12-week, open-label, Phase 3b study to examine
the safety, efficacy, and treatment satisfaction of
switching from epoprostenol GM to epoprostenol
AS in Japanese patients with PAH. The authors
hypothesized that switching from epoprostenol
GM to epoprostenol AS would improve treatment
satisfaction without increasing the incidence of




All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1975, as revised in
2000. Informed consent was obtained from all
patients for being included in the study.
Subjects
Patients aged C20 years at the time of informed
consent and who had pulmonary hypertension
classified as Group 1 using the Dana Point
classification [16,17] for pulmonary
hypertension were eligible if they had any of
the following: idiopathic pulmonary arterial
hypertension (IPAH), heritable pulmonary
arterial hypertension (HPAH), PAH associated
with drugs and toxins, or PAH associated with
connective tissue disease. Only patients who
had been treated with epoprostenol GM
for C3 months before enrollment and at a
stable dose for C30 days before the start of
study treatment were included in the study.
Females of childbearing potential had to have a
negative serum pregnancy test at screening.
They were also required to agree to take
monthly urine/serum pregnancy tests and to
use reliable contraceptives to avoid pregnancy
from the time of the screening visit until
30 days after the end of the study.
Eligible patients were excluded if they met
any of the exclusion criteria, such as diagnosis
of respiratory or cardiovascular disorder
requiring immediate surgery, presence of
confirmed or suspected pulmonary vein
occlusion, history of myocardial infarction,
and resting pulse rate of C120 beats/min.
Trial Drug
Epoprostenol AS (Actelion Pharmaceuticals
Japan Ltd.) was provided in 10-mL glass vials
containing 0.5 mg or 1.5 mg epoprostenol
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sodium. Epoprostenol AS was dissolved and
diluted by adding isotonic sodium chloride
solution. At the start of the 12-week treatment
period, epoprostenol GM was switched to an
equal dose of epoprostenol AS in the hospital.
For home therapy, epoprostenol was
administered via a central venous catheter by
continuous drip infusion using a portable
infusion pump.
Study Design
This was a two-site, open-label, single-arm,
Phase 3b study. The study consisted of a
2-week pretreatment screening period, a
12-week open-label treatment period (visiting
at baseline, week 1, 2, 4, 8, and 12), and a
continuous treatment period until marketing of
the study drug (visiting every 4 weeks).
Pulmonary hemodynamic measurements and
variables of clinical laboratory tests were
collected at baseline and week 12. Medical
interviews and checks for vital signs were
performed at each visit. Females of




The safety/tolerability endpoints were adverse
events occurring during the 12-week treatment
phase, together with changes from baseline to
week 12 for vital signs (blood pressure and heart
rate on the same arm in sitting or supine
position), body weight, and abnormal changes
from baseline to week 12 for clinical laboratory
tests (general biochemistry tests, including
thyroid function test and hematology test).
Vital signs and body weight were assessed at
each visit and clinical laboratory tests were
performed at baseline and week 12 (only
thyroid function was assessed every month).
Adverse events reported during the 12-week
evaluation period were coded according to
system organ class and terms using the
Medical Dictionary for Regulatory Activities/
Japanese version. The causality of adverse
events in relation to the trial drug was judged
by the investigators.
Efficacy Endpoints
The efficacy endpoints were changes in
pulmonary hemodynamic factors, WHO
functional class, and N-terminal prohormone
of brain natriuretic peptide (NT-proBNP)
concentrations from baseline (within 60 min
before the first dose of epoprostenol AS) to
immediately after switching (within 60 min
after the first dose of epoprostenol AS) or week
12. Pulmonary hemodynamic factors included
systolic pulmonary artery pressure, diastolic
pulmonary artery pressure, mean pulmonary
artery pressure, pulmonary capillary wedge
pressure, cardiac output, mean right atrial
pressure, mixed venous oxygen saturation,
cardiac index, pulmonary vascular resistance,
and pulmonary vascular resistance index.
Pulmonary hemodynamics were measured by
right heart catheterization, which was
performed according to standard local
procedures through the internal jugular,
subclavian, or femoral vein by a balloon
catheter placed into either the right or left
pulmonary artery in a sterilized cardiac
catheterization laboratory. Cardiac Output
(CO) was measured using Fick’s method [18].
Treatment Satisfaction
The abbreviated nine-item Treatment
Satisfaction Questionnaire for Medication
(TSQM-9), employed for the quality of life
assessment, is a validated questionnaire that
permits comparisons of patients’ treatment
462 Adv Ther (2013) 30:459–471
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satisfaction across medication types and patient
conditions [19]. The changes from baseline to
week 12 in treatment satisfaction were assessed
using the TSQM-9. This questionnaire includes
three items for each of three domains:
effectiveness, convenience, and global
satisfaction. The scores for each domain range
from 0 to 100, where higher scores indicate
higher satisfaction on that domain.
Statistical Analysis
This study was an exploratory study. No
hypothesis was set and no power
considerations were made for this study.
Patients who received at least one dose of the
study drug were included in the all-treated set
for analyses. Patients who had assessable data at
baseline and week 12 were included in the
analysis of pulmonary hemodynamics. All
statistical analyses were considered to be
exploratory and the significance level was set
at 5% (two-sided). The efficacy variables were
summarized descriptively by calculating the
mean, standard deviation, standard error,
median, 25th and 75th percentiles, minimum
and maximum. Changes from baseline were
examined using the Wilcoxon signed rank sum
test. All analyses were performed using SAS




The study was conducted at two Japanese study
sites, and started in October 2011. Eight
Japanese patients (one male, seven females)
with PAH were treated with the study drug
and completed the 12-week evaluation period
by October 2012. The characteristics of the
patients are summarized in Table 1 and
Supplemental Table 1. The mean (range) age
Table 1 Patient characteristics





Mean ± SD 47.6 ± 12.5
Median 46.0
[Min, Max] [25, 69]
Age in class
20–64 years 7 (87.5)
C65 years 1 (12.5)
Race, n (%)
Asian 8 (100.0)
Body mass index, kg/m2
Mean ± SD 19.94 ± 2.21
Median 20.40
[Min, Max] [15.4, 23.0]





Time since PAH diagnosis, years
Mean ± SD 6.21 ± 5.24
Median 5.26
[Min, Max] [0.6, 13.9]





APAH-CTD associated with pulmonary arterial hypertension-
connective tissue disease, APAH-DT associated with pulmonary
arterial hypertension-drugs and toxins induced, HPAH heritable
pulmonary arterial hypertension, IPAH idiopathic pulmonary
arterial hypertension, PAH pulmonary arterial hypertension, SD
standard deviation
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and time from PAH diagnosis were 47.6 (25–69)
years and 6.21 (0.6–13.9) years, respectively. At
baseline, seven patients had IPAH and one had
HPAH. The WHO functional class was Class I for
one patient, Class II for five patients, and Class
III for two patients. Epoprostenol AS was started
at the same dose of epoprostenol GM, with a
mean (range) dose of 40.13 (17.0–61.0) ng/kg/
min. The mean (range) duration of exposure to
epoprostenol AS during the 12-week treatment
period was 86.9 (78.4–91.6) days. There were no
dose adjustments in any patient. All of the
patients completed the study schedule during
the evaluation period. The continuous
treatment period was ongoing as of February
2013.
Safety
Adverse events reported during the 12-week
evaluation period are summarized in Table 2
according to system organ class and preferred
term using the Medical Dictionary for
Regulatory Activities/Japanese version. Seven
out of eight patients (87.5%) experienced a
total of 18 adverse events. Three patients
(37.5%) experienced a total of four adverse
events that were considered related to the
study drug. Two patients (25.0%) experienced
serious adverse events: moderate pneumonia
and mild device dislocation in one patient each,
both of which were not considered related to
the study drug. There were no deaths or adverse
events leading to treatment discontinuation
during the study. Seven out of eight patients
(87.5%) experienced mild adverse events and
three (37.5%) experienced moderate adverse
events; there were no severe adverse events.
The most frequent event was nausea, which was
reported by two patients. The other adverse
events occurred in one patient only. There were
no clinically significant changes from baseline
to week 12 in blood pressure, heart rate, body
weight, or clinical laboratory tests.
Efficacy
Table 3 shows the hemodynamic factors
measured within 60 min before (i.e., baseline)
and 60 min after the first dose of epoprostenol,
as well as the changes between these two times.
As shown in Table 3, there were no marked
changes in pulmonary hemodynamic
parameters from 60 min before to 60 min after
the first dose of epoprostenol AS. Wilcoxon
signed rank sum tests revealed no significant
differences at the 5% level for the changes from
baseline. Table 4 presents the hemodynamic
factors measured at baseline and at week 12,
together with their changes between these
times. As shown in Table 4, there were no
remarkable changes in pulmonary
hemodynamic factors from baseline to week
12. Additionally, Wilcoxon signed rank sum
tests revealed no significant differences at the
5% level for the changes from baseline. The
WHO functional class was unchanged from
baseline to week 12, as one was categorized as
Class I, five as Class II, and two as Class III
(Table 5). The mean (range) NT-proBNP
concentration was 139 (57–240) pg/mL at
baseline and 106 (41–243) pg/mL at week 12.
The mean (range) change from baseline to week
12 was -–43.3 (-196 to 43) pg/mL, which was
not clinically significant (Wilcoxon signed rank
sum test: P = 0.5781) (Fig. 1).
Treatment Satisfaction
Table 6 shows the scores for all three domains of
the TSQM-9 recorded at baseline and week 12,
together with the changes from baseline to
week 12. As shown in this table, there were
improvements in all three domains during the
464 Adv Ther (2013) 30:459–471
123
Table 2 Summary of treatment-emergent adverse events by intensity and system organ class
Asymptomatic Mild Moderate Severe Total (n5 8)
All system organ classes
Total pts with at least one AE 0 (0.0%) 7 (87.5) 3 (37.5%) 0 (0.0%) 7 (87.5%)
Total number of AEs 0 11 7 0 18
Gastrointestinal disorders
Total pts with at least one AE 0 (0.0%) 3 (37.5%) 3 (37.5%) 0 (0.0%) 5 (62.5%)
Total number of AEs 0 3 3 0 6
Nausea 0 (0.0%) 0 (0.0%) 2 (25.0%) 0 (0.0%) 2 (25.0%)
Diarrhea 0 (0.0%) 0 (0.0%) 1 (12.5%) 0 (0.0%) 1 (12.5%)
Gastritis 0 (0.0%) 1 (12.5%) 0 (0.0%) 0 (0.0%) 1 (12.5%)
Vomiting 0 (0.0%) 1 (12.5%) 0 (0.0%) 0 (0.0%) 1 (12.5%)
Mikulicz’s disease 0 (0.0%) 1 (12.5%) 0 (0.0%) 0 (0.0%) 1 (12.5%)
Infections and infestations
Total pts with at least one AE 0 (0.0%) 1 (12.5%) 2 (25.0%) 0 (0.0%) 3 (37.5%)
Total number of AEs 0 1 2 0 3
Pharyngitis 0 (0.0%) 0 (0.0%) 1 (12.5%) 0 (0.0%) 1 (12.5%)
Pneumonia 0 (0.0%) 0 (0.0%) 1 (12.5%) 0 (0.0%) 1 (12.5%)
Cellulitis 0 (0.0%) 1 (12.5%) 0 (0.0%) 0 (0.0%) 1 (12.5%)
General disorders and administrations site conditions
Total pts with at least one AE 0 (0.0%) 2 (25.0%) 0 (0.0%) 0 (0.0%) 2 (25.0%)
Total number of AEs 0 2 0 0 2
Device dislocation 0 (0.0%) 1 (12.5%) 0 (0.0%) 0 (0.0%) 1 (12.5%)
Injury associated with device 0 (0.0%) 1 (12.5%) 0 (0.0%) 0 (0.0%) 1 (12.5%)
Skin and subcutaneous tissue disorders
Total pts with at least one AE 0 (0.0%) 2 (25.0%) 0 (0.0%) 0 (0.0%) 2 (25.0%)
Total number of AEs 0 3 0 0 3
Dermatitis allergic 0 (0.0%) 1 (12.5%) 0 (0.0%) 0 (0.0%) 1 (12.5%)
Drug eruption 0 (0.0%) 1 (12.5%) 0 (0.0%) 0 (0.0%) 1 (12.5%)
Rash 0 (0.0%) 1 (12.5%) 0 (0.0%) 0 (0.0%) 1 (12.5%)
Ear and labyrinth disorders
Total pts with at least one AE 0 (0.0%) 1 (12.5%) 0 (0.0%) 0 (0.0%) 1 (12.5%)
Total number of AEs 0 1 0 0 1
Vertigo 0 (0.0%) 1 (12.5%) 0 (0.0%) 0 (0.0%) 1 (12.5%)
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12-week treatment period. The improvement in
convenience was statistically significant
(Wilcoxon signed rank sum test: P = 0.0313).
DISCUSSION
The results of this study demonstrate that patients
with PAH can be switched from epoprostenol GM
to a new formulation of epoprostenol sodium,
epoprostenol AS, with no apparent safety
concerns or deteriorations in pulmonary
hemodynamic factors. Switching from
epoprostenol GM to epoprostenol AS was also
associated with an improvement in convenience
across three treatment satisfaction domains.
The new formulation of epoprostenol is
stable for 24 h at room temperature (1–30 C)
after preparation/dilution in saline, and the
prepared solution does not require cooling with
a frozen gel pack, which is expected to improve
the quality of life of patients, particularly in
terms of their daily activities. This expectation
is supported by the results of the treatment
satisfaction questionnaire, which showed an
improvement in convenience. Therefore,
patients with PAH treated with conventional
formulations of epoprostenol sodium could be
switched to epoprostenol AS, a stable
formulation at room temperature, and may
enhance their quality of life through
improvements in treatment convenience.
The outdoor air temperature during the
summer in many regions of Japan often
exceeds 30 C, and the temperature around the
medication cassette of the diluted solution
could be even higher [20]. As part of the risk-
management strategy in this study, patients
were instructed to use a frozen gel pack during
the summer, especially when the
environmental temperature exceeded room
temperature. In this study, two out of eight
patients used a frozen gel pack during the
treatment period, but neither of these patients
experienced any changes in their overall
Table 2 continued
Asymptomatic Mild Moderate Severe Total (n5 8)
Musculoskeletal and connective tissue disorders
Total pts with at least one AE 0 (0.0%) 1 (12.5%) 0 (0.0%) 0 (0.0%) 1 (12.5%)
Total number of AEs 0 1 0 0 1
Arthralgia 0 (0.0%) 1 (12.5%) 0 (0.0%) 0 (0.0%) 1 (12.5%)
Nervous system disorders
Total pts with at least one AE 0 (0.0%) 0 (0.0%) 1 (12.5%) 0 (0.0%) 1 (12.5%)
Total number of AEs 0 0 1 0 1
Hypoasthesia 0 (0.0%) 0 (0.0%) 1 (12.5%) 0 (0.0%) 1 (12.5%)
Respiratory, thoracic and mediastinal disorders
Total pts with at least one AE 0 (0.0%) 0 (0.0%) 1 (12.5%) 0 (0.0%) 1 (12.5%)
Total number of AEs 0 0 1 0 1
Pleurisy 0 (0.0%) 0 (0.0%) 1 (12.5%) 0 (0.0%) 1 (12.5%)
AE adverse event, pts patients
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condition. In addition, the earthquake and
tsunami that hit eastern Japan on March 11,
2011, exposed flaws in the systems used to
ensure patient safety and maintain a stable
supply of medical resources during an
emergency [21]. If essential utilities such as
electricity and water networks are shut down
following a disaster, it is likely that frozen gel
packs would not be available, which may be a
life-threatening issue for patients with PAH. The
authors speculate that epoprostenol AS, which
is stable for a longer time at room temperature
than the GM formulation, could be valuable for
continuing medical treatment during
emergencies, and may have a positive impact
on the quality of medical care, although
additional examination of epoprostenol AS use
is required in situations where the temperature
exceeds 30 C. Further studies are needed to
evaluate the impact of higher environmental
temperatures on the safety/tolerability and
efficacy of this formulation, and to accumulate
evidence supporting its clinical use.
Some limitations of this study warrant
mention. Firstly, the sample size was small,
which may prevent detection of small
differences in hemodynamic factors or
infrequent adverse events. Secondly, as the study
was conducted inanopen-labelmannerwithouta
control group (e.g., of patients continuing
epoprostenol GM during the 12-week treatment
phase), it is possible that a study effect or patient
bias contributed to the observed improvements in
treatment satisfaction.
CONCLUSION
In conclusion, the present study showed that
switching to a new formulation of epoprostenol
was associated with an improvement in
convenience in relation to treatment
satisfaction, without unexpected adverse
Table 5 Changes in WHO FC from baseline to week 12
WHO FC
Baseline Week 12
I II III IV
N N [N] [N] [N] [N]
8 I 1 1 – – –
II 5 – 5 – –
III 2 – – 2 –
IV 0 – – – 0
FC functional class, WHO World Health Organization
Fig. 1 NT-proBNP concentration measured at baseline
and at week 12. P = 0.5781 at the 5% level (Wilcoxon
signed rank sum test) NT-proBNP N-terminal prohor-
mone of brain natriuretic peptide
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events or deteriorations in pulmonary
hemodynamic factors. Prospective studies in a
larger group of patients are needed to confirm
the safety of this formulation in long-term
clinical use. Epoprostenol AS was approved in
February 2013 in Japan as a generic drug with
the same potency and effectiveness as the
originally approved drug, epoprostenol GM. As
intravenous epoprostenol sodium therapy may
result in high medical costs, the introduction of
cheaper generic drugs may help to reduce
medical expenditure for treating PAH.
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